AI versus doctor for planning your next eye injections
Part of Eyes & vision, Heart & circulation clinical trials.
This study compares how well an artificial intelligence (AI) program decides on anti-VEGF eye injections versus a doctor's decision for conditions like wet macular degeneration, diabetic macular edema, and retinal vein occlusion. If you've already finished your initial loading doses, participating could help show whether AI can guide your future treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of these eye conditions: wet age-related macular degeneration, diabetic macular edema, or retinal vein occlusion.
- You must have already completed the initial round of anti-VEGF injections (the 'loading dose').
- You must be willing to have OCT imaging (a painless eye scan) and attend follow-up visits for 3 months.
- You cannot have had any eye surgery in the past 6 months.
- You must not have serious medical conditions or mental health issues that could interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a computer program (artificial intelligence) can use your eye scan images to help diagnose certain eye conditions. It might help catch problems earlier or more accurately, which could lead to better treatment.
This study tests whether an AI system can help eye doctors write clearer and more accurate reports on retinal images (photos of the back of the eye). The focus is on how doctors and AI work together to describe eye findings.
This study tests whether showing doctors an AI-generated second opinion on retinal scans changes their treatment decisions for patients with a specific eye disease (nAMD, a common cause of vision loss). It aims to see if the AI helps doctors make better choices.
This Phase 4 study tests an artificial-intelligence (AI) system used in real-world care for people with “wet” age-related macular degeneration. The goal is to help doctors monitor and treat the eye more accurately and safely over time.
This trial uses artificial intelligence to help diagnose eye conditions from digital eye images. If you have certain types of eye images from regular check-ups, your data might help teach the AI to recognise diseases better.
This trial uses artificial intelligence to help doctors make better decisions about eye disease. It analyzes your medical records and images to see how AI can improve care and track disease.
Hear when a new Neovascular (Wet) Age-Related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.